Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants
Status:
Recruiting
Trial end date:
2022-04-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of multiple doses of carbamazepine on
single- dose tepotinib pharmacokinetics in healthy participants. Study details include: Study
Duration: up to about 10 weeks; Treatment Duration: single dose of tepotinib on Days 1 and
26, 25 days of treatment with carbamazepine (Days 8 to 32); Visit Frequency: residence in the
Clinical Research Unit from Days -1 to 4 and Days 25 to 29, ambulatory daily visits from Days
5 to 24 and 30 to 33, and one ambulatory visit on Day 39.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany